Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epicorticosterone SCHEMBL19465689 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Corticosterone SCHEMBL22612 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL14592717 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Corticosterone SCHEMBL5669349 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL4380327 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL20058459 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL9070639 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL15920519 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL21168995 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL20242898 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183807-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | ANTARES PHARMA, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9757385-B2 | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds | MERCK SHARP & DOHME CORP. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170157141-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-06-08 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170029437-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH- DIRECTOR DEITR | 2017-02-02 | — | — | US | disclosed |
| US-20150335704-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GELS AND METHODS FOR FABRICATING THEREOF | IMPRIMIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157141-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | CCR10, HRH4, H1-10 | SMN1; SMN2 1191/4885HIF1A 2998/4885NR3C2 147/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | SMN1; SMN2 4177/4885HIF1A 2842/4885NR3C2 3266/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | SMN1; SMN2 4030/4885HIF1A 1270/4885NR3C2 689/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | SMN1; SMN2 2078/4885HIF1A 221/4885NR3C2 3040/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | SMN1; SMN2 4177/4885HIF1A 2842/4885NR3C2 3266/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | SMN1; SMN2 2078/4885HIF1A 221/4885NR3C2 3040/4885 |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | SMN1; SMN2 4517/4885HIF1A 2068/4885NR3C2 288/4885 |
| US-20170029437-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | BRPF3, EP300, BRD3 | SMN1; SMN2 4030/4885HIF1A 1270/4885NR3C2 689/4885 |
| US-20150335704-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GELS AND METHODS FOR FABRICATING THEREOF | PDE6G, PDE6D, PDE6H | SMN1; SMN2 2700/4885HIF1A 3072/4885NR3C2 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.